Display options
Cite
Alhakamy NA, Badr-Eldin SM, Ahmed OAA, et al. Piceatannol-Loaded Emulsomes Exhibit Enhanced Cytostatic and Apoptotic Activities in Colon Cancer Cells. Antioxidants (Basel). 2020;9(5)doi: 10.3390/antiox9050419.
Alhakamy, N. A., Badr-Eldin, S. M., Ahmed, O. A. A., Asfour, H. Z., Aldawsari, H. M., Algandaby, M. M., Eid, B. G., Abdel-Naim, A. B., Awan, Z. A., Alghaith, A. F., Alaofi, A. L., Mohamed, A. I., Okbazghi, S. Z., Al-Rabia, M. W., & Fahmy, U. A. (2020). Piceatannol-Loaded Emulsomes Exhibit Enhanced Cytostatic and Apoptotic Activities in Colon Cancer Cells. Antioxidants (Basel, Switzerland), 9(5), . https://doi.org/10.3390/antiox9050419
Alhakamy, Nabil A, et al. "Piceatannol-Loaded Emulsomes Exhibit Enhanced Cytostatic and Apoptotic Activities in Colon Cancer Cells." Antioxidants (Basel, Switzerland) vol. 9,5 (2020). doi: https://doi.org/10.3390/antiox9050419
Alhakamy NA, Badr-Eldin SM, Ahmed OAA, Asfour HZ, Aldawsari HM, Algandaby MM, Eid BG, Abdel-Naim AB, Awan ZA, Alghaith AF, Alaofi AL, Mohamed AI, Okbazghi SZ, Al-Rabia MW, Fahmy UA. Piceatannol-Loaded Emulsomes Exhibit Enhanced Cytostatic and Apoptotic Activities in Colon Cancer Cells. Antioxidants (Basel). 2020 May 13;9(5). doi: 10.3390/antiox9050419. PMID: 32414040; PMCID: PMC7278770.
Copy Download .nbib Format: NLM
Share it on

Antioxidants (Basel). 2020 May 13;9(5). doi: 10.3390/antiox9050419.

Piceatannol-Loaded Emulsomes Exhibit Enhanced Cytostatic and Apoptotic Activities in Colon Cancer Cells.

Antioxidants (Basel, Switzerland)

Nabil A Alhakamy, Shaimaa M Badr-Eldin, Osama A A Ahmed, Hani Z Asfour, Hibah M Aldawsari, Mardi M Algandaby, Basma G Eid, Ashraf B Abdel-Naim, Zuhier A Awan, Adel F Alghaith, Ahmed L Alaofi, Amir I Mohamed, Solomon Z Okbazghi, Mohammed W Al-Rabia, Usama A Fahmy

Affiliations

  1. Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  2. Advanced Drug Delivery Research Group, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  3. Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  4. King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  5. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
  6. Department of Medical microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University. Jeddah 21589, Saudi Arabia.
  7. Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  8. Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
  9. Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  10. Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 12372, Saudi Arabia.
  11. Department of Pharmaceutics and Industrial Pharmacy, Military Medical Academy, Cairo 11757, Egypt.
  12. Global Analytical and Pharmaceutical Development, Alexion Pharmaceuticals, New Haven, CT 06510, USA.

PMID: 32414040 PMCID: PMC7278770 DOI: 10.3390/antiox9050419

Abstract

Piceatannol (PIC), a naturally occurring polyphenolic stilbene, has pleiotropic pharmacological activities. It has reported cytotoxic activities against different cancer cells. In the present study, PIC emulsomes (PIC-E) were formulated and assessed for cytotoxic activity. A Box-Behnken design was employed to investigate the influence of formulation factors on particle size and drug entrapment. After optimization, the formulation had a spherical shape with a particle size of 125.45 ± 1.62 nm and entrapment efficiency of 93.14% ± 2.15%. Assessment of cytotoxic activities indicated that the optimized PIC-E formula exhibited significantly lower IC

Keywords: HCT 116 cells; apoptosis; emulsomes; mitochondrial membrane potential; piceatannol; reactive oxygen species

Conflict of interest statement

The authors declare no conflicts of interest, the funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the de

References

  1. Int J Nanomedicine. 2014 Jun 12;9:2891-903 - PubMed
  2. Biotechniques. 2011 Feb;50(2):98-115 - PubMed
  3. J Drug Deliv. 2013;2013:165981 - PubMed
  4. Apoptosis. 2003 Mar;8(2):115-28 - PubMed
  5. Breast Cancer Res Treat. 2011 Apr;126(2):529-37 - PubMed
  6. Biochem Biophys Res Commun. 2013 Jan 18;430(3):1164-8 - PubMed
  7. Gut. 2017 Apr;66(4):683-691 - PubMed
  8. Front Bioeng Biotechnol. 2020 Feb 11;8:50 - PubMed
  9. Methods Mol Biol. 2019;1894:123-131 - PubMed
  10. Biochem Biophys Res Commun. 2014 Sep 26;452(3):775-81 - PubMed
  11. Cancer Lett. 2014 Oct 10;353(1):1-7 - PubMed
  12. Nutr Cancer. 2009;61(6):847-54 - PubMed
  13. Toxicol Appl Pharmacol. 2019 May 1;370:65-77 - PubMed
  14. Biomed Pharmacother. 2019 Sep;117:109142 - PubMed
  15. J Microencapsul. 2013;30(3):225-36 - PubMed
  16. Curr Pharm Biotechnol. 2015;16(4):392-405 - PubMed
  17. Pharmaceutics. 2019 Jan 01;11(1): - PubMed
  18. Microbiol Immunol. 2004;48(10):729-36 - PubMed
  19. J Liposome Res. 2019 Dec;29(4):383-398 - PubMed
  20. Mol Nutr Food Res. 2008 Apr;52(4):408-18 - PubMed
  21. Beilstein J Nanotechnol. 2019 Sep 24;10:1933-1942 - PubMed
  22. BJU Int. 2018 Apr;121(4):527-533 - PubMed
  23. J Pharm Pharmacol. 2006 Mar;58(3):321-6 - PubMed
  24. Biochem Pharmacol. 1988 Jul 1;37(13):2607-11 - PubMed
  25. FASEB J. 2008 Jul;22(7):2185-97 - PubMed
  26. Anticancer Res. 2010 Nov;30(11):4587-93 - PubMed
  27. Cell Physiol Biochem. 2016;39(4):1404-20 - PubMed
  28. Int J Pharm. 2009 Oct 1;380(1-2):181-8 - PubMed
  29. Mutat Res. 2012 Jan-Mar;750(1):60-82 - PubMed
  30. Avicenna J Med Biotechnol. 2016 Apr-Jun;8(2):75-83 - PubMed
  31. J Nanobiotechnology. 2013 Dec 06;11:37 - PubMed
  32. Cancers (Basel). 2020 Jan 01;12(1): - PubMed
  33. Nanomaterials (Basel). 2019 Apr 19;9(4): - PubMed
  34. Food Chem Toxicol. 2013 Nov;61:3-8 - PubMed
  35. Colloids Surf B Biointerfaces. 2015 Apr 1;128:132-139 - PubMed
  36. Int J Mol Med. 2018 Sep;42(3):1427-1435 - PubMed
  37. Oxid Med Cell Longev. 2019 Dec 4;2019:2075614 - PubMed
  38. Cancer Res. 2009 May 1;69(9):3918-26 - PubMed
  39. J Biol Chem. 2013 Aug 16;288(33):23740-50 - PubMed
  40. Fitoterapia. 2011 Jun;82(4):513-23 - PubMed
  41. J Agric Food Chem. 2016 Feb 3;64(4):725-37 - PubMed
  42. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 1;926:21-7 - PubMed
  43. PLoS One. 2015 Oct 30;10(10):e0141778 - PubMed

Publication Types

Grant support